But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.

Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.

Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.